PharmaFocus Today – Page 12 – media

Breaking news, Johnson & Johnson Medical Global Vice President resigns

Not long ago, Larry Jones, Global Vice President and Group Chief Information Officer of Johnson & Johnson MedTech, announced his decision to resign. On the LinkedIn platform, Jones recalled fondly: “Looking back on the 35 glorious years spent at Johnson & Johnson, my heart is filled with deep nostalgia for the extraordinary times we have gone through together.” During his tenure in Johnson & Johnson’s medical device department, Jones was particularly committed to promoting the company’s innovation in oncology, orthopedics, cardiovascular and general surgery, and realizing the innovation of digital surgical connection solutions through advanced technologies such as surgical robots and machine learning platforms. As a senior technology executive, Jones has rich leadership experience. During his decades in office, he has led many major projects in Johnson & Johnson’s pharmaceutical and medical device departments, including the recent three-year, $200 million global digital transformation plan. According to LinkedIn information, Jones is ...
- Source: drugdu
- 45
- November 5, 2024
COVID-19 drugs have become a “dark horse”

The success and failure of COVID-19 are the market’s summary of Pfizer in the past few years. In 2022, COVID-19 vaccines and COVID-19 oral drugs brought Pfizer up to $57 billion in revenue. Relying on the wealth brought by COVID-19 products, Pfizer’s revenue exceeded $100 billion this year, setting a new record for the highest revenue of major pharmaceutical companies. However, as the COVID-19 pandemic dissipated, the global market demand for COVID-19 products fell sharply, and Pfizer was the first to bear the brunt. Faced with the “COVID-19 cliff”, Pfizer had to continue to lower its revenue expectations, and the company’s stock price continued to fall. Last year, it fell by more than 40% throughout the year, and its market value evaporated by nearly $130 billion. In this year’s third quarter report, Pfizer handed in a report card that far exceeded market expectations. Revenue in the third quarter reached $17.7 ...
- Source: drugdu
- 48
- November 5, 2024
After the guidelines were adjusted, GlaxoSmithKline’s RSV vaccine sales plummeted by 74%

Star vaccine products suffered a Waterloo. Last year, the RSV vaccine was amazing; this year, it fell back quickly. Recently, GlaxoSmithKline released its financial report, and its RSV vaccine Arexvy’s sales in the third quarter fell 74% year-on-year, with sales of 188 million pounds, equivalent to 240 million US dollars. So, what caused the decline of Arexvy? According to GlaxoSmithKline, Arexvy suffered a triple blow. The core is that the US Centers for Disease Control and Prevention (CDC) has narrowed the scope of immunization recommendations. Previously, RSV vaccines were recommended for vaccination for people over 60 years old. In June of this year, the US CDC adjusted its recommendations for vaccination populations. After the adjustment, the scope was greatly narrowed, limited to: 1. Adults aged 75 and above. 2. High-risk groups aged 60-74. In addition, the US CDC recommends that it be used only as a single lifetime vaccination. In ...
- Source: drugdu
- 42
- November 5, 2024
Hengrui Medicine’s “2 Category 1 new drugs” approved for clinical trials

Recently, according to the official website of CDE, two Class 1 new drugs of Hengrui Medicine have obtained implicit approval for clinical trials, namely HRS-5632 injection and HRS-6208 capsule. The former is intended to treat lipoprotein disorders, and the latter targets solid tumors. Lipoprotein disorders Lipoprotein disorder refers to the abnormal metabolism of plasma lipoproteins. Studies have shown that it may lead to abnormal transport and distribution of lipids in the blood, thus causing a series of health problems. At present, lipoprotein disorder has been confirmed to be an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), and there is no specific drug to treat it. It is reported that cardiovascular diseases, mainly ASCVD, are the leading cause of death among urban and rural residents in China, accounting for more than 45% of the causes of death. In response to lipoprotein disorder, Hengrui Medicine has deployed a small molecule drug ...
- Source: drugdu
- 56
- November 5, 2024
single-cell transcriptomics and proteomic analysis

Parkinson’s disease is a common neurodegenerative disorder characterized by movement disorders, autonomic dysfunction, and sleep cognitive problems, affecting nearly 6 million people worldwide. Its neuropathological features include the loss of dopaminergic neurons and the aggregation of alpha synuclein within cells. Although neuroinflammation involving glial cells and immune cells is believed to be related to the pathogenesis of Parkinson’s disease, further research is needed to determine whether these pathways are associated with sporadic diseases. In addition, the relative contributions of neurons and glial cells in Parkinson’s pathology are still unclear. Although single-cell technology, including multi omics analysis, is gradually becoming a popular method for studying neurodegenerative diseases, these tools are only now beginning to be applied in Parkinson’s disease research, especially utilizing human brain tissue. On October 30, 2024, the Zhang Le research group at Yale University published a research paper titled “Single cell transcriptomic and proteomic analysis of Parkinson’s disease ...
- Source: drugdu
- 67
- November 4, 2024
Nat Commun | Professor Ouyang Songying’s team reveals the activation mechanism of Sir2 HerA system in pathogenic bacteria’s phage immunity

In the long-term and intense survival competition between bacteria, archaea, and bacteriophages, they have evolved various complex antiviral systems to resist the invasion of bacteriophages. The latest research reveals that approximately 7% of sequenced bacterial genomes have at least one defense system, among which the depletion of nicotinamide adenine dinucleotide (NAD+) is a common strategy to combat phage induced miscarriage infections. The hydrolysis of NAD+is mainly performed by proteins containing TIR and Sir2 domains. Recently, Professor Ouyang Songying’s team from the School of Life Sciences at Fujian Normal University collaborated to publish a paper titled “Mechanical Basis for the Allosteric Activation of NADase Activity in the Sir2 HerA Antiphage Defense System” online in Nature Communications. This study uses bioinformatics, structural biology, and experimental techniques such as biochemistry to reveal the molecular mechanism of how the Sir2 HerA system is activated and exerts its anti phage function in pathogen immunity.The Sir2 ...
- Source: drugdu
- 55
- November 4, 2024
16 billion yuan! Novartis “runs” to enter the market

Recently, the molecular glue star company Monte Rosa Therapeutics announced that it has reached a global exclusive development and commercialization license agreement with Novartis to advance the development of molecular glue protein degraders targeting VAV1, including the research therapy MRT-6160. Under the terms of the agreement, Novartis agreed to pay Monte Rosa an advance payment of US$150 million. In addition, Monte Rosa is eligible to receive up to US$2.1 billion in development, regulatory and sales milestone payments (US$2.25 billion is approximately RMB 16 billion). Monte Rosa Therapeutics is headquartered in Boston, USA. The company was founded in 2018 and is a biotechnology company focusing on the development of molecular glue drugs. Its core technology platform is the QuEEN platform, which is mainly dedicated to the discovery and development of molecular glue drugs. Under the terms of the agreement, Monte Rosa will continue to be responsible for completing the ongoing Phase ...
- Source: drugdu
- 45
- November 4, 2024
Domestic PD-L1 was approved in the UK for the first time

CStone Pharmaceuticals announced today (October 31) that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab combined with platinum-containing chemotherapy for patients without EGFR sensitive mutations, or without ALK, ROS1, First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with RET genomic tumor variants. This is the second marketing authorization application approval for sugalimab in overseas markets, following the approval by the European Commission. The approval was mainly based on the results of a multi-center, randomized, double-blind Phase III clinical study – GEMSTONE-302. Sugemalimab combined with chemotherapy can significantly extend the progression-free survival and overall survival of patients with newly treated metastatic NSCLC compared with placebo combined with chemotherapy. The research data has been published in The Lancet Oncology and Nature Cancer, and has been presented in oral and poster presentations at many international academic conferences. CStone Pharmaceuticals has reached a strategic cooperation with ...
- Source: drugdu
- 46
- November 4, 2024
Aimei Vaccine’s 13-Valent Conjugate Pneumococcal Vaccine Obtains Production License and Market Registration Submitted

On November 1, Aimei Vaccine announced that it has submitted a drug market registration application for its self-developed 13-valent conjugate pneumococcal vaccine to the National Medical Products Administration. The results from a completed Phase III clinical study show that Aimei’s 13-valent conjugate pneumococcal vaccine has demonstrated good immunogenicity and safety, meeting the clinical preset objectives. Aimei’s wholly-owned subsidiary, Aimei Biotechnology Co., Ltd., has obtained the corresponding drug production license for this product. The 13-valent conjugate pneumococcal vaccine has been referred to as the “king of global vaccines” and has been the world’s top-selling vaccine for ten consecutive years. Pfizer’s 13-valent conjugate pneumococcal vaccine (Prevnar 13®) is the best-selling vaccine globally and has frequently ranked among the top ten best-selling drugs worldwide. According to Pfizer’s 2023 annual report, global sales of Pfizer’s pneumococcal conjugate vaccine were approximately $6.44 billion in 2023. Over the years, the global sales of the 13-valent conjugate ...
- Source: drugdu
- 43
- November 4, 2024
Lizhong Group Reports Net Profit of 1.673 Billion Yuan in First Three Quarters, Revenue Declines for Five Consecutive Quarters

China Net Finance, November 1 – In the context of an expanding centralized procurement and a cool market for innovative drugs, Lizhong Group has still managed to maintain profit growth. The third-quarter report shows that the company achieved a net profit of 500 million yuan in a single quarter, a year-on-year increase of 7.45%. For the first three quarters, the cumulative net profit attributable to shareholders reached 1.673 billion yuan, which represents a year-on-year growth of 4.44%. The net profit after eliminating non-recurring gains and losses was approximately 1.631 billion yuan, up by 3.51%. In contrast to profit growth, Lizhong Group’s revenue has shown a downward trend. In the first three quarters, the company reported approximately 9.082 billion yuan in operating revenue, a year-on-year decline of 5.94%. From a quarterly perspective, Lizhong Group’s revenue has been declining for five consecutive quarters, with the first three quarters of this year reporting ...
- Source: drugdu
- 41
- November 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.